Emerging therapeutic targets for idiopathic pulmonary fibrosis: preclinical progress and therapeutic implications

Toyoshi Yanagihara, Ciaran Scallan, Kjetil Ask, Martin R.J. Kolb

Research output: Contribution to journalReview articlepeer-review

6 Citations (Scopus)

Abstract

Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with high associated morbidity and mortality. The therapeutic landscape has significantly changed in the last 20 years with two drugs currently approved that have demonstrated the ability to slow disease progression. Despite these developments, survival in IPF is limited, so there is a major interest in therapeutic targets which could serve to open up new therapeutic avenues. Areas covered: We review the most recent information regarding drug targets and therapies currently being investigated in preclinical and early-stage clinical trials. Expert opinion: The complex pathogenesis of IPF and variability in disease course and response to therapy highlights the importance of a precision approach to therapy. Novel technologies including transcriptomics and the use of serum biomarkers, will become essential tools to guide future drug development and therapeutic decision making particularly as it pertains to combination therapy.

Original languageEnglish
Pages (from-to)939-948
Number of pages10
JournalExpert Opinion on Therapeutic Targets
Volume25
Issue number11
DOIs
Publication statusPublished - 2021
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Fingerprint

Dive into the research topics of 'Emerging therapeutic targets for idiopathic pulmonary fibrosis: preclinical progress and therapeutic implications'. Together they form a unique fingerprint.

Cite this